Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

B1532

Sigma-Aldrich

Resorufin benzyl ether

CYP450 substrate, ≥98% (TLC), powder

Synonyme(s) :

7-Benzyloxy-3H-phenoxazin-3-one, 7-Benzyloxyresorufin, O7-Benzylresorufin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C19H13NO3
Numéro CAS:
87687-02-3
Poids moléculaire :
303.31
Numéro MDL:
MFCD00171613
Code UNSPSC :
12352204
ID de substance PubChem :
24891597
Nomenclature NACRES :
NA.32

Nom du produit

Resorufin benzyl ether, CYP450 substrate

Niveau de qualité

200

Essai

≥98% (TLC)

Forme

powder

Solubilité

chloroform: 9.80-10.20 mg/mL, clear, orange

Température de stockage

2-8°C

Chaîne SMILES 

O=C1C=CC2=Nc3ccc(OCc4ccccc4)cc3OC2=C1

InChI

1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2

Clé InChI

XNZRYTITWLGTJS-UHFFFAOYSA-N

Substrats

Fluorimetric substrate for cytochrome P450-linked enzymes.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H315,H319,H335

Classification des risques

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000300650
0000300650
0000235437
0000229250
0000229250

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Proadifen hydrochloride analytical standard, ≥95%

Supelco

P1061

Proadifen hydrochloride

Seth Kwabena Amponsah et al.
Evidence-based complementary and alternative medicine : eCAM, 2020, 7956493-7956493 (2020-07-28)
There is considerable evidence that many patients concurrently administer dietary supplements with conventional drugs, creating a risk for potential drug-supplement interaction. The aim of this study was to determine the effect of Cellgevity® supplement on selected rat liver cytochrome P450
Lana X Garmire et al.
Pharmaceutical research, 24(12), 2171-2186 (2007-08-19)
Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. We used the synthetic modeling method. Specialized software
Shosaku Kashiwada et al.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 141(4), 338-348 (2005-08-23)
Phylogenic analysis of the teleost genomic lineages has demonstrated the precedent for multiple genome duplications. Among many of the genes duplicated, cytochrome P450 genes have undergone independent diversification, which can be traced to a single ancestral gene. In teleosts, cytochrome
Nantana Nuchtavorn et al.
Analytica chimica acta, 1098, 86-93 (2020-01-18)
Cytochrome P450 (CYP450), and in particular CYP3A4, is the most abundantly expressed CYP450 isozyme implicated in many drug-drug and medicinal plant-drug interactions. Therefore, incorporation of CYP3A4 enzyme screening at an early stage of drug discovery is preferable in order to
R D Verschoyle et al.
The Journal of pharmacology and experimental therapeutics, 265(1), 386-391 (1993-04-01)
The O-dealkylation of pentoxyresorufin, a substrate for P450 2B1, was decreased in lung microsomes from rats dosed with O,O,S-trimethylphosphorodithioate, O,O,O-trimethylphosphorothioate, bromophos, fenitrothion, p-xylene and 2,4-dichloro-(6-phenylphonoxy)ethylamine. This activity was decreased by antibodies to P450 2B1 but unaffected by antibodies to P450
Afficher tous les articles scientifiques apparentés

Articles

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique